60 Degrees Pharmaceuticals Completes $1M Private Placement for Operations

Key Facts

In a move reflecting the ongoing capital needs of the biotech sector, 60 Degrees Pharmaceuticals has finalized a private placement of its common stock. According to reports, the company completed the sale of 574,713 shares at a price of $1.74 per share, raising approximately $1 million in gross proceeds. The firm, which specializes in medicines for vector-borne diseases, intends to utilize the capital for working capital and general corporate purposes.

This capital raise was conducted alongside H.C. Wainwright & Co to bolster the company's financial position. Per analyst data, the offering included the issuance of Series A and B warrants with specific exercise terms, highlighting a strategic effort to secure operational funding. While the capital is essential for the company's biotech business, such fixed-price placements often present a dilutive risk to existing equity holders.

With current market price levels for SXTP unavailable at this time, investor focus remains on the company's ability to execute its clinical and corporate goals following this cash injection. On the macroeconomic front, market participants are looking toward upcoming US Consumer Confidence data in late July 2026 as a broader indicator of sentiment within the healthcare and small-cap investment landscape.